Report error Found 18 Enz. Inhib. hit(s) with all data for entry = 8937
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 2.80nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 3.5nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 3.70nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 5.20nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 5.60nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 7.20nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 8.20nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 11nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 11.4nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
Affinity DataIC50: 4.46E+3nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 L containing 1% DMSO. Recombinant Human catalytic domains of M...More data for this Ligand-Target Pair
Affinity DataIC50: 4.63E+3nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 L containing 1% DMSO. Recombinant Human catalytic domains of M...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 L containing 1% DMSO. Recombinant Human catalytic domains of M...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 L containing 1% DMSO. Recombinant Human catalytic domains of M...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 L containing 1% DMSO. Recombinant Human catalytic domains of M...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 L containing 1% DMSO. Recombinant Human catalytic domains of M...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 L containing 1% DMSO. Recombinant Human catalytic domains of M...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 L containing 1% DMSO. Recombinant Human catalytic domains of M...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 L containing 1% DMSO. Recombinant Human catalytic domains of M...More data for this Ligand-Target Pair
